FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Has reported global Phase 3 topline results for its oral dementia candidate and signed a global rights deal with Fosun Pharma.

  • Signed an exclusive AR1001 rights deal with Fosun Pharma. Source
  • Announced that the POLARIS-AD monotherapy group met the primary endpoint. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Data & AI

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

AriBio

Develops AR1001, an oral PDE5-inhibiting candidate for Alzheimer's disease, and ran a global Phase 3 trial with 1,535 patients in 13 countries.

AR1001

Phase 3

An oral candidate for early Alzheimer's disease that met the primary endpoint (CDR-SB) in the 604-patient monotherapy group of the global Phase 3 POLARIS-AD trial.

POLARIS-AD extension study

Phase 3

A long-term extension study for participants who completed 52 weeks of treatment in POLARIS-AD.

Completion reported

Signed an exclusive AR1001 rights deal with China's Fosun Pharma covering regions outside Korea, the Middle East and Latin America, and received $10 million of the upfront payment.

Completion reported

Presented POLARIS-AD topline results at CTAD 2026, with the monotherapy group meeting the primary endpoint.

Official role guide

AriBio careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 아리바이오 "치매약 3상 효과…美FDA 허가 추진" ↗뉴시스 · Published 2026-11-17 · Sources checked 2026-11-18 · Original unavailable
  2. 아리바이오 '먹는 치매약' 글로벌 상업화 채비…9월 승부수 ↗전자신문 · Published 2026-05-18 · Sources checked 2026-11-18 · Original unavailable
  3. 아리바이오, 7조 기술수출 '선급금' 1000만불 조기 수령 ↗파이낸셜뉴스 · Published 2026-05-26 · Sources checked 2026-11-18 · Original unavailable